Over D4-D7, recipient age at baseline, the main cause of end-stage renal disease, CYP3A phenotype, dyslipidemia at baseline and hematocrit, total bilirubin and plasma creatinine over the time period influenced tacrolimus exposure. This evidence concerns the gene CYP3A4 and chronic kidney disease.